BROOMFIELD, Colo.--(BUSINESS WIRE)--ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases, announced that on January 28, 2009, its common stock will commence trading on the NASDAQ Global Market under the symbol “ABIO.” This follows the merger on January 27, 2009 of a wholly-owned subsidiary of Nuvelo, Inc. with the company formerly known as ARCA biopharma, Inc. The combined Company is named ARCA biopharma, Inc. (“ARCA”).
